Mathieu Coinçon

Title: The Innovative Contributions of Mathieu Coinçon

Introduction

Mathieu Coinçon is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of peptides that can induce immune responses against certain viruses. His work is characterized by a focus on antigenic epitopes, which are crucial for vaccine development.

Latest Patents

Coinçon holds a patent titled "Antigenic epitopes from EBV gp350/220 and uses thereof." This invention relates to a peptide that comprises specific amino acid sequences designed to bind to monoclonal antibodies. The peptide is intended for use in immunizing or vaccinating animals against herpesviruses, such as Epstein-Barr virus (EBV). The patent highlights the potential for this peptide to induce the production of neutralizing antibodies, which is vital for effective vaccination strategies.

Career Highlights

Throughout his career, Mathieu Coinçon has worked with various organizations, including Valorisation-Recherche, Limited Partnership and Valorisation Hsj, Limited Partnership. His experience in these companies has allowed him to collaborate on innovative projects that advance the field of immunology and vaccine development.

Collaborations

Coinçon has collaborated with notable professionals in his field, including Caroline Alfieri and Jurgen Sygusch. These collaborations have contributed to the successful development of his patented technologies and have fostered advancements in the understanding of immune responses.

Conclusion

Mathieu Coinçon's work exemplifies the importance of innovation in biotechnology. His patented peptide represents a significant step forward in the fight against herpesviruses, showcasing his commitment to advancing medical science.